In ALCL, the catalytic domain of the ALK protein was fused with the amino terminus of nucleophosmin (NPM), and it was found that the NPM-ALK fusion protein results in constitutive activation of the ALK tyrosine kinase, thereby leading to deregulation of multiple cell signalling pathways and increased tumorigenicity2. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.